

Organic Pharm. Chemistry for Pharmacy Students

By

Professor Dr. Mohie Sharaf El Din







DRUG DISTRIBUTION

- <u>A drug</u> is a chemical molecule.
- Following introduction into the body, <u>a drug must pass</u> <u>through many barriers</u>, survive alternate sites of attachment and storage, and avoid significant metabolic destruction before <u>it reaches the site of action</u>, usually <u>a</u> <u>receptor on</u> or <u>in</u> a cell.
- At the receptor, the following equilibrium usually holds:
 a. Drug + Receptor ≒ [Drug Receptor] Complex

→ Pharmacologic Response

b. [Drug – Receptor] Complex \leftrightarrows Drug \rightarrow excretion in the circulatory system

- The ideal drug molecule will show favourable binding characteristics to the receptor, and the equilibrium will lie to the right.
- At the same time, the drug will be expected to dissociate from the receptor and re-enter the systemic circulation to be excreted.
- Major <u>exceptions</u> include :
- 1. <u>the alkylating agents used in cancer chemotherapy</u>.
- 2. a few <u>inhibitors of the enzyme acetyl</u> <u>cholinesterase.</u>
- 3. suicide inhibitors of monoamine oxidase.

- These <u>pharmacological agents form covalent</u> <u>bonds with the receptor</u>, usually an enzyme's active site.
- In these cases, the cell must destroy the receptor or enzyme, or, in the case of the alkylating agents, the cell would be replaced, ideally with a normal cell.

Oral Administration


- Assume that the drug is administered orally. The <u>drug must go into solution</u> to pass through the gastrointestinal mucosa.
- Even drugs administered as true solutions may not remain in solution as they enter the acidic stomach and then pass into the alkaline intestinal tract.

The ability of the drug to dissolve is governed by several factors, including:

(factors affecting solubility)


- 1. its chemical structure,
- 2. variation in particle size and particle surface area,
- 3.nature of the crystal form,
- 4.type of tablet coating, and type of tablet matrix.


- A. varying the dosage form and physical characteristics of the drug, it is possible to have a drug dissolve quickly or slowly, with the latter being the situation for many of the sustained-action products.
- An example is orally administered <u>sodium</u> <u>phenytoin</u>, with which variation of both the <u>crystal form</u> and <u>tablet adjuvants</u> can significantly <u>alter the bioavailability</u> of this drug widely used in the treatment of epilepsy.



sodium phenytoin


- <u>B. Chemical modification</u> is also used to a limited extent to facilitate a drug reaching its desired target.
- An example is **olsalazine**, used in the treatment of ulcerative colitis. This drug is a dimer of the pharmacologically active mesalamine (5aminosalicylic acid). The latter is not effective orally because it is metabolized to inactive forms before reaching the colon. The dimeric form passes through a significant portion of the intestinal tract before being cleaved by the intestinal bacteria to two equivalents of mesalamine.






- As illustrated by olsalazine, any compound passing through the gastrointestinal tract will encounter a large number and variety of digestive and bacterial enzymes, which, in theory, can degrade the drug molecule.
- In practice, a new drug entity under investigation will likely be dropped from further consideration <u>if it</u> <u>cannot survive in the intestinal tract or its oral</u> <u>bioavailability is low</u>, <u>necessitating parenteral dosage</u> <u>forms only.</u>
- An exception would be a drug for which there is no effective alternative or which is more effective than existing products and can be administered by an alternate route, <u>including parenteral</u>, <u>buccal</u>, or <u>transdermal</u>. In contrast, these same digestive enzymes can be used to advantage.

- <u>Chloramphenicol</u> is water soluble enough (2.5 mg/mL) to come in contact with the taste receptors on the tongue, producing an unpalatable bitterness.
- To mask this intense bitter taste, <u>the palmitic acid</u> moiety is added as an <u>ester of chloramphenicol's</u> <u>primary alcohol</u>. [pulmetic acid :Its chemical formula is CH₃(CH₂)₁₄COOH].
- This reduces the parent drug's water solubility (1.05 mg/mL), enough so that it can be formulated as a suspension that passes over the bitter taste receptors on the tongue.
- Once in the intestinal tract, the ester linkage is hydrolyzed by the digestive esterases to the active antibiotic chloramphenicol and the very common dietary fatty acid palmitic acid.



- Olsalazine and chloramphenicol palmitate are examples of " <u>Prodrugs</u> ".
- Most <u>prodrugs</u> are compounds that <u>are inactive</u> in their native form but are easily metabolized to the active agent.
- Occasionally, the prodrug approach <u>is used to</u> <u>enhance the absorption of a drug</u> that is poorly absorbed from the gastrointestinal tract.
- <u>Enalapril</u> is the <u>ethyl ester of enalaprilic acid</u>, an active inhibitor of angiotensin converting enzyme (ACE). The ester prodrug is much more readily absorbed orally than the pharmacologically active carboxylic acid.



- Unless the drug is intended to act locally in the gastrointestinal tract, it will have to pass through the gastrointestinal mucosal barrier into venous circulation to reach the site of the receptor.
- The drug's route involves distribution or partitioning between the aqueous environment of the gastrointestinal tract, the lipid bilayer cell membrane of the mucosal cells, possibly the aqueous interior of the mucosal cells, the lipid bilayer membranes on the venous side of the gastrointestinal tract, and the aqueous environment of venous circulation.

Parenteral Administration


- Many times, there will be therapeutic advantages in bypassing the intestinal barrier by using parenteral (injectable) dosage forms. This is common in:
- 1.patients who, because of illness,
- 2. cannot tolerate or are incapable of accepting drugs orally.
- 3.Some drugs are so rapidly and completely metabolized to inactive products in the liver (first-pass effect) that oral administration is precluded.

- Intravenous administration places the drug directly into the circulatory system, where it will be <u>rapidly</u> distributed throughout the body, including tissue depots and the liver, where most biotransformations occur, in addition to the receptors.
- Subcutaneous and intramuscular injections <u>slow</u> <u>distribution of the drug</u>, because it must diffuse from the site of injection into systemic circulation.
- Intraspinal and intracerebral routes will <u>place the</u> <u>drug directly into the spinal fluid or brain</u>, respectively. This bypasses a specialized epithelial tissue, the blood-brain barrier, which protects the brain from exposure to a large number of metabolites and chemicals.

- <u>Local anesthetics</u> are examples of <u>administration</u> of a drug directly onto the desired nerve.
- A spinal block is a form of anesthesia performed by <u>injecting a local anesthetic directly into the</u> <u>spinal cord at a specific location</u> to block transmission along specific neurons.
- These parenteral routes produce a depot in the tissues , from which the drug must reach the blood or lymph.
- Once in systemic circulation, the drug will undergo the same distributive phenomena as orally and intravenously administered agents before reaching the target receptor.

- In general, the same factors that control the drug's passage through the gastrointestinal mucosa will also determine the rate of movement out of the tissue depot.
- The prodrug approach can also be <u>used to alter</u> <u>the solubility characteristics</u>, which, in turn, can <u>increase the flexibility in formulating dosage</u> <u>forms</u>.
- The solubility of <u>methylprednisolone</u> can be altered from essentially water insoluble <u>methylprednisolone acetate</u> to <u>water-soluble</u> <u>methylprednisolone sodium succinate</u>.

Methyl prednisolone



- <u>The water-soluble sodium hemisuccinate salt</u> <u>is used in oral</u>, <u>intravenous</u>, and <u>intramuscular</u> <u>dosage forms</u>.
- Methylprednisolone itself is normally found in tablets.
- The insouble acetate ester is found in topical ointments and sterile aqueous suspensions for intramuscular injection.
- Both the succinate and acetate esters are hydrolyzed to the active methylprednisolone by the patient's own systemic hydrolytic enzymes (esterases).

Protein Binding

- Once the drug enters the systemic circulation , it can undergo several events.
- A-It may stay in solution,
- B-but <u>many drugs will be bound to the serum</u> proteins, usually albumin.
- Thus, a new equilibrium must be considered. Depending on the equilibrium constant, the <u>drug can remain in systemic circulation bound</u> <u>to albumin for a considerable period</u> and not be available to the sites of biotransformation, the pharmacological receptors, and excretion.

Protein binding can have a profound effect on: 1.<u>Biodistribution</u>,


2.<u>Half-life</u> in the body


3. also <u>can prolong the drug's duration of action</u>. The drug– protein complex is too large to pass through the renal glomerular membranes, preventing rapid excretion of the drug.

- <u>4.The drug's effective solubility</u>
- A drug with such poor water solubility that therapeutic concentrations of the unbound (active) drug normally cannot be maintained, still can be a very effective agent.
- The <u>albumin-drug complex acts as a reservoir</u> by providing large enough concentrations of free drug to cause a pharmacological response at the receptor.

- <u>5. Protein binding may also limit access to</u> <u>certain body compartments</u>.
- The placenta is able to block passage of proteins from maternal to fetal circulation. Thus, <u>drugs that normally would be expected</u> to cross the placental barrier and possibly <u>harm the fetus</u> are retained in the maternal circulation, bound to the mother's serum proteins.

- <u>6. Interaction with other drugs.</u>
- The drug-protein binding phenomenon can lead to some clinically significant drug-drug interactions that <u>result when one drug displaces</u> <u>another from the binding site on albumin</u>.
- A large number of <u>drugs can displace the</u> <u>anticoagulant warfarin from its albumin-binding</u> sites. <u>This increases the effective concentration of</u> <u>warfarin at the receptor</u>, leading to an increased prothrombin time and potential haemorrhage.





• Questions :

1. The drug is combine with cell at (receptors)

- 2. The drug absorbed from the stomach in form of (solution)
- 3. The factors that affect the absorption of a drug include
- 4. Sustained-action drugs usually dissolve
- 5. Parenteral dosage forms are used when
- 6. What are the alternate route of administration when a drug cannot taken orally ?

- 7. What is a prodrug ?
- 8. Give example of a prodrug.
- 9. What is the main uses of prodrugs ?
- 10. When parenteral administration is nesccary ?
- 11. What are the different parenteral routs ?
- 12. Biotransformations occur in theand.....?
- 13. Local anesthetics are examples of administration of a drug directly onto?
- 14. Many drugs will be bound to the serum proteins, usually?
- 15. What are the effects of Protein binding ?